Identification of new possible targets for leukemia treatment by kinase activity profiling
Arja ter Elst(University Medical Center Groningen), Eveline S.J.M. de Bont(Hôpital Saint-Michel), Sander H. Diks, Frank J.G. Scherpen, Rob Ruijtenbeek(PamGene (Netherlands)), Maikel P. Peppelenbosch(Erasmus MC), Piet J. Boender(PamGene (Netherlands)), Peter M. Hoogerbrugge(Helios Klinikum Emil von Behring), Kim R. Kampen(VIB-KU Leuven Center for Cancer Biology), Willem A. Kamps(Pediatric Oncology Group), Arend H. Sikkema
Cited by 21
Related Papers
Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood
|The Lancet|1998|964
A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study
|The Lancet Oncology|2009|932
Evidence Based Selection of Housekeeping Genes
|PLoS ONE|2007|772
Outcome of Treatment in Children with Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia
|New England Journal of Medicine|2000|599
Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial
|Journal of Clinical Oncology|2015|419